Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

How Does Cannabis Impact Inflammation Markers in EDS? 

Posted
Updated
ByMy Patient Advice
Author: Dr. Clarissa Morton, PharmD

Many Ehlers-Danlos Syndrome (EDS) patients are exploring cannabis for inflammation in EDS to help manage swelling, pain, and tissue damage. Emerging studies suggest cannabis may influence inflammatory markers, offering a new avenue for symptom management. As inflammation is a key concern in EDS, understanding how cannabis works could guide more effective treatment strategies. 

Can I treat my condition with Medical Cannabis?

How Cannabis May Reduce Inflammation in EDS 

Evidence points to cannabinoids, especially CBD, playing a role in the body’s inflammatory response. Here’s how cannabis may help EDS patients: 

  • CBD Anti-Inflammatory Effects: 
    CBD has been shown to lower levels of cytokines, proteins involved in inflammation, potentially easing joint swelling and tissue irritation linked to EDS swelling. 
  • Immune System Modulation: 
    Cannabis may influence the immune system, helping to balance inflammation responses. This could reduce chronic inflammation often experienced by EDS patients and improve overall tissue health. 
  • Pain and Swelling Reduction: 
    By reducing inflammatory markers, cannabis can indirectly ease pain and swelling. Some studies measuring biomarkers show lower inflammation after prolonged cannabinoid use, hinting at cannabis results for symptom relief. 

What This Means for EDS Management 

Cannabis for inflammation in EDS shows promise in regulating inflammation, though most evidence comes from small studies or indirect measures. More research is needed to confirm its impact on EDS-specific inflammatory markers. 

If you’re considering cannabis to address inflammation in EDS, it’s wise to consult a healthcare professional.  

Visit providers like LeafEase for personalised consultations on integrating cannabis into your care plan. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to medical cannabis and Ehlers-Danlos Syndrome.

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Categories